Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYD Dengue Vaccine Dosing Schedules and JE Co-administration
NCT01943825Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2013
- Primary completion
- Nov 2015
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (4 arms), sponsored by Sanofi. Primary endpoints: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains and Number of Participants With Antibody Titers Greater Than or Equal to 10 (1/Dilution). Started Nov 2013; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT01943825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01943825.